Neurocognitive Correlates of the Influence of Number Word Syntax on Magnitude Processing
NCT ID: NCT07133230
Last Updated: 2025-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
84 participants
OBSERVATIONAL
2025-09-30
2027-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Domain-general and Domain-specific Contributions to the Development of Numerical Cognition
NCT06658392
Effect of Normal Aging on Language Processing
NCT02189460
Brain and Eye Markers of Facial Expression Recognition and Disorders Associated with Autistic Symptoms
NCT05635812
Neuroanatomy of Reading in Congenital Deafness.
NCT00400413
Language Acquisition in the Brain and Algorithms: Towards Systematic Monitoring of the Evolution of Semantic Representations in Biological and Artificial Neural Networks
NCT05217043
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Call for participants for pre-selection
* Sending of information forms by mail
* Making an appointment for the inclusion visit at GHU Paris
* Information on the modalities, constraints and foreseeable risks of the study
* Collection of informed consent
* Verification of inclusion/non-inclusion criteria
* Clinical examination:
* Verification of medical history and drug treatments
* Psychiatric pathology
* Consumption of toxic substances (nicotine, alcohol, cannabis, etc.)
* Manual lateralization will be assessed by the score on the Edinburgh questionnaire (Oldfield, 1971)
* Collection of main medical history and concomitant treatments
* Explanation of study procedures
* MRI examination
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants recruited (phase 1)
In each experimental phase (2 in total), 42 adult volunteers will be recruited (a total of 84 participants), selected based on the following criteria:
* Aged 18-45
* Female or male
* Right-handed
* Signed informed consent
* Normal medical, neurological, and neuroradiological examinations
* Affiliated with a social security system
* For women of childbearing age: under effective contraception; a urine pregnancy test will be administered
* MRI examination compatible Participants will be recruited in the Paris region.
No interventions assigned to this group
Participants recruited (phase 2)
In each experimental phase (2 in total), 42 adult volunteers will be recruited (a total of 84 participants), selected based on the following criteria:
* Aged 18-45
* Female or male
* Right-handed
* Signed informed consent
* Normal medical, neurological, and neuroradiological examinations
* Affiliated with a social security system
* For women of childbearing age: under effective contraception; a urine pregnancy test will be administered
* MRI examination compatible Participants will be recruited in the Paris region.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female or male;
* Right-handed preference;
* Subject, or legal representative, who has given consent to participate;
* Native language: French
* Subject affiliated with a social security system;
* Having signed their consent to participate (and their legal representative if applicable),
* Subjects have read the information letter and given their free and informed consent;
* Normal medical, neurological, and neuroradiological examinations
* For women of childbearing age, be on effective contraception
Exclusion Criteria
* Subject with contraindications to an MRI examination (pacemaker or neurosensory stimulator or implantable defibrillator, cochlear implants, ferromagnetic foreign bodies in the eyes or brain near neural structures, metal prostheses, patient agitation: non-cooperative or agitated patients, minors, claustrophobic subjects, pregnant women, ventriculoperitoneal neurosurgical shunt valves, dental braces);
* Subject with chronic alcohol or drug use;
* Abuse or dependence on substances (except nicotine) or toxic substances for more than 5 years or having led to comas (overdoses);
* Subject with sudden-onset cognitive disorders that could indicate a stroke; a history of head trauma with loss of consciousness for more than 1 hour, or encephalitis;
* Subject with chronic neurological, psychiatric, endocrine, hepatic, or infectious conditions;
* Subject with a history of major illness (diabetes, chronic lung disease, severe cardiac, metabolic, hematological, endocrine, or immunological disorder, cancer);
* Subject on medication: taking medications likely to interfere with brain imaging measurements (psychotropics, anxiolytic hypnotics, neuroleptics, anti-Parkinsonians, benzodiazepines, steroidal anti-inflammatories, antiepileptics, central analgesics, and muscle relaxants);
* Color blindness;
* Inability to comply with the study for geographical or psychiatric reasons;
* Tattoo incompatible with MRI;
* Cerebral palsy;
* Fine motor skills disorder;
* Pregnant women at the time of inclusion;
* Adult subjects under legal protection or unable to give consent (article L.1121-8 of the French Public Health Code) (under guardianship or curatorship);
* Children and parents under legal protection measures
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier St Anne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GHU Ste Anne
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Elise KLEIN
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D24-P010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.